View Press Releases
-
NoriZite™ Nasal Spray blocks infection with Omicron SARS-CoV-2 variant in cell culture
New evidence demonstrates that NoriZite creates a physical barrier to prevent viral infection
Dec 14, 2022
-
physIQ’s eVO2Max™ demonstrates breakout ability to estimate cardiopulmonary functional capacity from wearable sensor data during daily routine activity
physIQ today announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable biosensors and deep neural network technology. This innovative biomarker, eVO2Max, can be generated using 24 hours of continuous vital signs and activity data captured during routine daily activities. This enables remote assessment at higher frequency and convenience than by in-clinic tests of cardiopulmonary functional capacity, such as the gold standard, cardiopulmonary exercise test (CPET), and the less accurate surrogate six-minute walk test (6MWT).
Dec 13, 2022
-
PubHive Upgrades Life Science Literature Workflow SaaS Platform
PubHive Navigator’s Fetch version 2.0 features new content curator and consumer roles, expanded data input and output options, integration capabilities, plus a simplified consumer user interface
Dec 13, 2022
-
Form Bio Brings Accelerated Genomic Analysis to Bioinformatics with NVIDIA Clara Parabricks
Form Bio, the breakthrough computational life sciences platform, today announced the integration of the NVIDIA Clara Parabricks suite of genomic analysis tools with Form Bio’s genomic analysis workflows. The integrated solution, provided by Form Bio, enables scientists, bioinformaticians and other life science professionals to execute genomic workflows with acceleration fueled by GPU parallelization and deep learning AI tools.
Dec 13, 2022
-
Vaxess Announces Interim Results from Phase I ClinicalTrial of MIMIX-Flu Vaccine Patch
Company focused on creating shot-free future of vaccines and expanding vaccine access; first human trial of Vaxess patch-based influenza vaccine showed strong safety and immunogenicity profiles
Dec 13, 2022
-
InSysBio to release Immune Response Template for QSP modeling in Oncology
InSysBio launches the Oncology version of Immune Response Template (IRT). IRT in Oncology represents a QSP platform of immune system in cancer, simultaneously being a tool for development of QSP and mechanistic models related to tumor-specific immune response.
Dec 13, 2022
-
Quartic.ai Addresses Process Development Capacity Constraints with AI-Powered PD Optimization
New innovation delivers optimal product conditions in fewer runs, reducing raw materials costs, and shaving weeks off of Process Development campaigns
Dec 14, 2022
-
Qlucore participates in major EU project to prevent cardiovascular diseases
Qlucore will be participating in a major EU project that is working to improve preventative treatment for patients at risk of cardiovascular diseases, such as heart attacks and strokes.
Dec 13, 2022
-
Three Featured Products Upgraded at Alfa Chemistry: Protection Reagents, Environmental Goods Standards, Porphyrins and Phthalocyanines
On the occasion of Thanksgiving and Christmas, Alfa Chemistry would like to express its sincere gratitude to its global customers. In addition to discounts and exquisite gifts offered to ordering customers, the company also continuously improves its product lines. Fairly recently, Alfa Chemistry announced the upgrade of its featured products, i.e., protection reagents, environmental goods standards, as well as porphyrins and phthalocyanines, supporting better user experience and wider choices for customers across the world.
Dec 13, 2022
-
CD Formulation Launches One-stop OEM/ODM and Analytical Testing Solutions for Cosmetics
The past decade has seen exponential growth of the cosmeceutical market in the personal care industry. There is increasing use of alpha hydroxy acids for skin rejuvenation as well as the use of vitamin C in topical formulations as an antioxidant. In response to such a trend, CD Formulation recently launched one-stop OEM/ODM and analytical testing solutions for cosmetic formulations.
Dec 13, 2022
-
Curebase Releases Diagnostic Offering that Delivers First All-Inclusive Package of Software and Services Needed to Fully Execute Diagnostic Studies
Start-up trials achieved in eight to 12 weeks, a fraction of typical timeframe
Dec 12, 2022
-
InsightRX Provides Máxima Medical Center with Precision Dosing Guidance
Large teaching hospital in the Netherlands relies on precision dosing platform for point-of-care decision support and immunology research
Dec 12, 2022
-
Triad HealthCare Network Harnesses Medication Data to Improve Outcomes for High-Risk Patients
DrFirst’s MedHx PRM Provides Quick Access to Prescription Fill Information So Healthcare Providers Can Intervene Early to Prevent Readmissions and Optimize Outcomes
Dec 12, 2022
-
CluePoints Appoints Andy Cooper as New Chief Executive Officer
CluePoints Appoints Andy Cooper as New Chief Executive Officer New CEO brings a combination of experience and drive as CluePoints rapidly scales its RBQM and Data Quality Oversight offerings
Dec 12, 2022
-
Inizio acquires Evolution Road, bolstering Evoke’s digital innovation and omnichannel offering
-
Icosagen Chooses Genedata Biologics to Digitalize Recombinant Antibody Discovery
Leading CRDMO implements market-leading platform to streamline its biotherapeutics discovery workflow and data exchange with biopharma customers
Dec 11, 2022
-
MultiCare Partners with IllumiCare to Offer Clinical Trials at Point-of-Care with Trials App
MultiCare Health System is the first to use the Illumicare Trials App in a clinical setting, streamlining clinical trial recruitment and increasing awareness among providers, patients and clinical research teams.
Dec 11, 2022
-
Digital Therapeutics Alliance and Curebase release publication setting the stage for a fit-for-purpose evidence standard for digital therapeutics (DTx)
Digital Therapeutics Alliance and Curebase release publication setting the stage for a fit-for-purpose evidence standard for digital therapeutics (DTx)
Dec 11, 2022
-
Tesis Biosciences Announces Proposed Study of Veterans and Civilians with Mild Traumatic Brain Injury
Tesis Biosciences Announces Proposed Study of Veterans and Civilians with Mild Traumatic Brain Injury - Company in preparation for formal FDA approval submission
Dec 11, 2022
-
New Draper Study Showcases Powerful New Way to Evaluate Kidney Toxicity
A new study by scientists at Draper adds to the toolbox researchers can use in understanding the biological processes underway in organ-chips. They discovered a new indicator of toxicity in kidney-chips.
Dec 1, 2022